Frontiers

Explore biotech.

Understanding and engineering biology, from discovery to useful treatment.

The big story

The GLP-1 pill is here. Who is it reaching?

New prescription data offer an early look at who gets oral semaglutide. A different way to take a medicine is not the same as wider access to care.

8 Oct 2026 3 min read

Read article

Biotech

One DNA Letter Can Reroute a Gene’s Control Wiring

A new single-allele map shows how an autoimmune-risk variant creates a molecular boundary that blocks a distant enhancer from reaching SESN3.

Biotech 3 Oct 2026 3 min read

Biotech

Retatrutide’s 20.8% Headline Has a Tougher Twin

The same Phase 3 trial produced an 18.8% result when researchers counted treatment interruptions and rescue therapy. The difference is not a contradiction—it is the part readers need to understand.

Biotech 1 Oct 2026 3 min read

Latest in Biotech

Biotech

The AI learns one patient. Then it lines up the X-ray.

A new Nature study uses patient-specific training to match flat X-rays with 3D scans in seconds. Better image alignment is not yet proof of safer surgery.

Biotech 30 Sep 2026 3 min read

Biotech

A Sjögren’s drug met its Phase 3 goal. The key number is missing.

Amgen reports a positive Phase 3 result in a trial of roughly 621 people. Until the effect size appears, the treatment benefit remains hard to judge.

BiotechReality Check 30 Sep 2026 3 min read

Biotech

These mice carry human cortical tissue—not human brains

Researchers removed most mouse cortical neurons before implanting human organoids. The grafts grew, connected and revealed injury—but remained immature, disorganized tissue inside a mouse nervous system.

Biotech 21 Sep 2026 4 min read

Biotech

These cell clusters give blood a new route

Pre-organized cell clusters improved blood-flow recovery in mice. Longer follow-up reveals the next challenge: keeping the new networks working.

Biotech 20 Sep 2026 3 min read

Biotech

A brain implant decodes words and gestures at once

Two people with paralysis used brain signals to display words and animate an avatar’s gestures. The experiment opens a bigger question: how much control does the person have over what the screen expresses?

Biotech 14 Sep 2026 3 min read

Biotech

The cancer drug designed to let go

Gotistobart's new lung-cancer data are striking. Its real test is whether molecular precision can produce a repeatable survival benefit.

Biotech 14 Sep 2026 5 min read

Biotech

This Fly Wiring Map Doesn’t Stop at the Neck

A map of nearly 167,000 neurons follows the male fruit fly’s nervous system through its neck. Its real power is helping researchers choose what to test next.

Biotech 7 Sep 2026 3 min read

Biotech

Daraxonrasib Shrinks Lung Tumors. Can It Buy More Time?

One RAS inhibitor, different cancers and different standards of proof. A study guide separates lung tumor activity from the randomized pancreatic results.

Biotech 5 Sep 2026 4 min read

Biotech

Hepcludex FDA Approval: What Bulevirtide Changes for Chronic Hepatitis D

FDA approval gives chronic hepatitis D a US treatment pathway. The harder question is whether evidence, diagnosis, price and payer access can catch up.

Biotech 6 Jun 2026 7 min read

The Vastkind Briefing

Stay ahead
of the story.

A personal take on the week. By Dorian.

Occasional editions. Free to subscribe.
Unsubscribe anytime.

Explore biotech.

The GLP-1 pill is here. Who is it reaching?

One DNA Letter Can Reroute a Gene’s Control Wiring

Retatrutide’s 20.8% Headline Has a Tougher Twin

Latest in Biotech

The AI learns one patient. Then it lines up the X-ray.

A Sjögren’s drug met its Phase 3 goal. The key number is missing.

These mice carry human cortical tissue—not human brains

These cell clusters give blood a new route

A brain implant decodes words and gestures at once

The cancer drug designed to let go

This Fly Wiring Map Doesn’t Stop at the Neck

Daraxonrasib Shrinks Lung Tumors. Can It Buy More Time?

Hepcludex FDA Approval: What Bulevirtide Changes for Chronic Hepatitis D

Stay ahead
of the story.

Check your inbox.

Explore Vastkind

Your reading list

Latest in Biotech

Stay aheadof the story.

Check your inbox.

Stay ahead
of the story.